Effect of US Food and Drug Administration’s Cardiovascular Safety Guidance on Diabetes Drug Development

The FDA’s 2008 cardiovascular safety guidance for diabetes drugs was associated with a 31% differential decrease in the rate of diabetes drugs entering phase II trials, though the remaining drugs were significantly more likely to target novel biological pathways, with no measurable improvement in glycemic efficacy among phase III candidates. The findings demonstrate how regulatory actions can substantially impact pharmaceutical innovation trajectories and drug development priorities.